Didem Arslan TAŞ, Ahmet Eftal YÜCE, Özgür ÖZYILKAN

Scleroderma after 5-fluorouracil and folinic acid therapy in a patient with colon carcinoma

Skleroderma cilt altında ve iç organlarda artmış kollajen birikimi ile karakterize bir bağ dokusu hastalığıdır. Etiyolojisi tam aydınlatılamamakla birlikte bazı kimyasal ajanların ve çevresel faktörlerin etyopatogenezde rol oynadığı kabul edilmektedir. Progresif sistemik skleroderma olan olgularda gastrointestinal kanal karsinomlarının arttığına dair sınırlı veri bulunmaktadır. Kolon karsinomu tedavisinde kullanılan 5-florourasil ile skleroderma ilişkisine dair literatürde sadece iki olgu bildirilmiştir. 5-florourasil ve folinik asit tedavisi verilen timik karsinomlu bir olguda ise skleroderma benzeri klinik tablo ve otoantikor pozitifliği bildirilmiştir. Bu yazıda, 51 yaşında kolon karsinomu tanısıyla 3 kür 5-florourasil ve folinik asit tedavisi alan ve daha sonra scleroderma geliştiren bir olgu sunulmuştur.

Anahtar Kelimeler:

Skleroderma, kolon kanseri, 5 florourasil

5-Florourasil ve folinik asit tedavisi alan kolon karsinomlu olguda tedavi sonrası skleroderma

Sistemic sclerosis is a connective tissue disease which is characterized by the increase amount of collagene in subcutaneous tissue and internal organs. Several chemical agents and environmental factors are accused fort he etiopathogenesis however the etiology is not clear. There is limited data abput the increased frequency of colon carcinoma in the cases with sistemic sclerosis. There are 2 cases in the literature about the association between scleroderma and 5-fluorouracil which is used for the treatment of colon carcinoma. Similar clinical course and autoantibody positivity was also reported in a patient with tymic carcinoma who had been treated with 5-FU and folinic acid. In this article, a 51-year-old woman who developed scleroderma after 5-FU and folinic acid therapy which had been started for colon carcinoma has been reported.

Keywords:

Scleroderma, colon cancer, 5 fluorouracil,

PDF

___

Rosenthal AK. Incidence of cancer among patients with systemic sclerosis. Cancer 1995;76:910-4.
Segel MC. Systemic sclerosis (scleroderma) and esophageal adenocarcinoma: Is increased patient screening necessary? Gastroenterology. 1985;89: 485Marmur R. Cancer-associated neuromusculetal syndromes. Recognizing the rheumatic-neoplastic connection. Postgrad Med. 2002;11:95-8. 101-2.
Casas jA. A new promising treatment in systemic sclerosis: 5-fluorouracil. Annals of the Rheumatic Diseases. 1987;46:763-7.
Akama H. Systemic sclerosis possibly caused by 5fluorouracil. N Y State J Med. 1991;91:35.
Emir S. Scleroderma in a child after chemotherapy for cancer. Clin Exp Rheumatol 2001;1982:221-3.
Yazışma Adresi / Address for Correspondence: Dr. Didem Arslan Taş Çukurova Üniversitesi Tıp Fakültesi, Romatolojiİmmünoloji Bilim Dalı 01330 Balcalı-ADANA
Email: arslan_didem@yahoo.com geliş tarihi/received :11.04.2013 kabul tarihi/accepted:27.05.2013